Related Experiment Videos
Complement-mediated acute effects of liposome-encapsulated hemoglobin
1Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA.
Summary
Liposome-encapsulated hemoglobin (LEH), a potential blood substitute, activates the complement system, causing adverse effects. Soluble complement receptor type I effectively inhibits these side effects, improving safety for emergency use.
Area of Science:
- Biomedical engineering
- Immunology
- Hematology
Background:
- Liposome-encapsulated hemoglobin (LEH) is a potential blood substitute.
- LEH has been shown to activate the complement (C) system in various species.
- Complement activation by LEH involves both classical and alternative pathways, partly mediated by anti-lipid antibodies.
Purpose of the Study:
- To investigate the role of complement activation in the adverse effects of LEH.
- To evaluate the efficacy of soluble complement receptor type I (sCR1) in inhibiting LEH-induced complement activation and associated side effects.
Main Methods:
- Studies were conducted on rats and pigs.
- Complement activation was assessed following LEH administration.
- Cardiopulmonary function and physiological changes were monitored.
- The inhibitory effect of sCR1 on LEH-induced complement activation and side effects was evaluated.
Main Results:
- LEH administration activates the complement system via classical and alternative pathways.
- Complement activation is linked to acute physiological and hematological changes, including pulmonary vasoconstriction and decreased cardiac output.
- These adverse effects, particularly cardiopulmonary distress, can be significantly inhibited by sCR1.
Conclusions:
- Complement activation is a primary cause of LEH-associated adverse effects.
- sCR1 is an effective inhibitor of LEH-induced complement activation and cardiopulmonary distress.
- Inhibition of complement activation may improve the safety profile of LEH for emergency blood substitution.